PPARG and breast carcinoma: Although data from human trials suggest the efficacy of TZDs as monotherapy in prostate cancer and glioma and as chemopreventive agents in colon, lung, and breast cancer, the action of TZDs are highly complex and those actions do not correlate with cellular PPARγ expression status and/or activation [59, 60].